Back to Search

A Phase 1 Dose-Escalation Study of SLV-154 in Subjects With Metastatic Solid Tumors

  • Protocol Number: 202502089
  • Principal Investigator: Van Tine, Brian
  • Cancer Types: Early Phase

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.

Protocol Interventions

Drug: SLV-154